This post was originally published on this site
The company’s shares plunged almost 14% in afternoon trading, hitting their lowest since listing last August.
The company said it will drop its application to the European Medicines Agency for regulatory approval of its first-generation vaccine candidate CVnCoV after late-stage trials delivered disappointing results with 47% efficacy in June.
There would be a potential overlap with approval timelines for a second-generation candidate.
The earliest potential approval of CVnCoV would have come in the second quarter of 2022 when the candidates from the second-generation vaccine program are expected to progress to late-stage clinical development by that time, CureVac said.
As a result, the advance purchase agreement the German company signed to sell shots to the European Union will end, it said.
It said it expects to start human trials for its second-generation shot in the next months, aiming for regulatory approval in 2022. Results from early-stage animal trials have shown the strong potential of the shot compared with the original one, it said.
